Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Caroline Robert, Vanna Chiarion‐Sileni et al.|European Journal of Cancer|2017Cited by 171
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.Pilar Garrido, Ulrik Lassen, Enriqueta Felip et al.|Journal of Clinical Oncology|2014Cited by 4
Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway SignalingPilar Garrido, Ulrik Lassen, Enriqueta Felip et al.|Annals of Oncology|2014Cited by 3